EA202092694A1 - Системы и способы количественного определения и модификации вязкости белков - Google Patents

Системы и способы количественного определения и модификации вязкости белков

Info

Publication number
EA202092694A1
EA202092694A1 EA202092694A EA202092694A EA202092694A1 EA 202092694 A1 EA202092694 A1 EA 202092694A1 EA 202092694 A EA202092694 A EA 202092694A EA 202092694 A EA202092694 A EA 202092694A EA 202092694 A1 EA202092694 A1 EA 202092694A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
systems
modification
quantitative determination
viscosity
Prior art date
Application number
EA202092694A
Other languages
English (en)
Inventor
Сяобинь Сюй
Амин Чжан
Юань Цао
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA202092694A1 publication Critical patent/EA202092694A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4005—Concentrating samples by transferring a selected component through a membrane
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4005—Concentrating samples by transferring a selected component through a membrane
    • G01N2001/4016—Concentrating samples by transferring a selected component through a membrane being a selective membrane, e.g. dialysis or osmosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material

Abstract

В данном изобретении предлагаются системы и способы определения областей белков, которые вносят вклад в вязкость составов этих белков. Также предлагаются способы модификации вязкости концентрированных белковых составов.
EA202092694A 2018-05-10 2019-05-09 Системы и способы количественного определения и модификации вязкости белков EA202092694A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862669440P 2018-05-10 2018-05-10
PCT/US2019/031438 WO2019217626A1 (en) 2018-05-10 2019-05-09 Systems and methods for quantifying and modifying protein viscosity

Publications (1)

Publication Number Publication Date
EA202092694A1 true EA202092694A1 (ru) 2021-03-12

Family

ID=66794086

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092694A EA202092694A1 (ru) 2018-05-10 2019-05-09 Системы и способы количественного определения и модификации вязкости белков

Country Status (14)

Country Link
US (1) US20190345196A1 (ru)
EP (1) EP3791189A1 (ru)
JP (1) JP2021523349A (ru)
KR (1) KR20210007958A (ru)
CN (1) CN112136049A (ru)
AR (1) AR115383A1 (ru)
AU (1) AU2019266275A1 (ru)
BR (1) BR112020021140A2 (ru)
CA (1) CA3095190A1 (ru)
EA (1) EA202092694A1 (ru)
MX (1) MX2020012016A (ru)
SG (1) SG11202009372UA (ru)
TW (1) TW202016125A (ru)
WO (1) WO2019217626A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230150300A (ko) * 2021-03-03 2023-10-30 리제너론 파마슈티칼스 인코포레이티드 단백질 점도를 정량화하고 변경시키기 위한 시스템 및 방법

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CA2423227C (en) * 2000-10-12 2011-11-29 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE60309238T2 (de) 2002-03-08 2007-06-06 Asml Netherlands B.V. Lithographische Maske, lithographischer Apparat und Verfahren zur Herstellung einer Vorrichtung
CN102585002A (zh) 2006-06-02 2012-07-18 瑞泽恩制药公司 人il-6受体的高亲和力抗体
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN101809037B (zh) 2007-07-31 2014-01-15 瑞泽恩制药公司 人cd20的人抗体及其使用方法
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
MX2011014008A (es) 2009-06-26 2012-06-01 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
CA2855822C (en) 2011-11-14 2022-11-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
EP2807190B1 (en) 2012-01-23 2018-12-26 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ang2 antibodies
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
AU2013302925B2 (en) 2012-08-13 2018-07-05 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
US9637535B2 (en) 2013-03-15 2017-05-02 Regeneron Pharmaceuticals, Inc. IL-33 antagonists and uses thereof
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
CA2940685C (en) 2014-03-11 2023-10-24 Regeneron Pharmaceuticals, Inc. Anti-egfrviii antibodies and uses thereof
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
ES2779070T3 (es) 2014-05-05 2020-08-13 Regeneron Pharma Animales con C5 y C3 humanizadas
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
US9657099B2 (en) 2014-09-16 2017-05-23 Regeneron Pharmaceuticals, Inc. Anti-glucagon antibodies
WO2016054598A2 (en) * 2014-10-03 2016-04-07 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
EA201790946A8 (ru) * 2014-12-01 2018-10-31 Зе Скриппс Рисёрч Инститьют Способы и композиции, связанные с функциональными полипептидами, встроенными в гетерологичные белковые каркасы
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體

Also Published As

Publication number Publication date
CN112136049A (zh) 2020-12-25
CA3095190A1 (en) 2019-11-14
AU2019266275A1 (en) 2020-11-05
JP2021523349A (ja) 2021-09-02
WO2019217626A1 (en) 2019-11-14
SG11202009372UA (en) 2020-10-29
BR112020021140A2 (pt) 2021-02-17
US20190345196A1 (en) 2019-11-14
MX2020012016A (es) 2021-01-29
AR115383A1 (es) 2021-01-13
TW202016125A (zh) 2020-05-01
EP3791189A1 (en) 2021-03-17
KR20210007958A (ko) 2021-01-20

Similar Documents

Publication Publication Date Title
EA202090090A1 (ru) Включение неприродных нуклеотидов и способы с ними
EA201890790A1 (ru) Связывающие pd-1 белки и способы их применения
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
EA201892691A1 (ru) Однодоменный белок, связывающий сывороточный альбумин
EA201890423A1 (ru) Слитые белки фактора ix, способы их получения и применения
EA201991168A1 (ru) Белок, связывающий простатический специфический мембранный антиген
EA201890247A1 (ru) Ингибиторы дезоксиуридинтрифосфатазы, содержащие гидантоин
EA202190726A1 (ru) Индольные ингибиторы арил-гидрокарбонового рецептора (ahr) и их применение
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
EA201991546A1 (ru) Антигенсвязывающие белки против нейропилина и способы их применения
EA201991912A1 (ru) Составы, содержащие pd-1-связывающие белки, и способы их получения
EA202092692A1 (ru) Аналоги рапамицина и их применения
EA202191785A1 (ru) Антитела к ctla4 и способы их применения
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
EA201792561A1 (ru) Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
EA202191656A1 (ru) Анти-il-36 антитела и способы их применения
EA202090084A1 (ru) Новый терапевтический ферментный слитый белок и его применение
EA202190810A1 (ru) Способы и наборы для получения цельной крови с инактивированным патогеном
EA202192786A1 (ru) Твердые формы (e)-3-[2-(2-тиенил)винил]-1h-пиразола
PH12020552270A1 (en) Anti-steap1 antigen-binding protein
EA201890177A1 (ru) Мультиспецифические связывающие белки
EA201991876A1 (ru) Антитела против фактора d и их применения